1. China Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A

Zhejiang Hisoar Pharmaceutical Co., Ltd. Class A

SSZSE:002099
5.84
CNY
+0.08
(+1.39%)
-0.11EPS
8.55BMarket Cap
Oct 28Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
1.77
1.73
1.72
1.62
1.48
1.71
1.83
1.55
1.57
1.54
1.34
1.23
1.23
1.29
Basic EPS, GAAP
-0.12
0.07
0.36
0.15
0.22
0.38
0.48
0.2
0.06
0.05
-0.26
-0.21
-0.06
-0.1
Free Cash Flow per Basic Share
-0.34
0.03
0.12
0.34
-0.02
0.34
0.28
0.29
-0.08
-0.04
0.05
0.03
-0.09
- -
Dividend per Share
0.08
0.07
0.12
0.13
0.07
0.13
0.3
0.3
0.03
0.11
0.07
0.02
0.02
0.02
Book Value per Share
0.96
2.2
2.36
2.94
3.17
3.33
3.54
3.62
3.78
3.77
3.46
3.17
3.11
2.96
Tangible Book Value per Share
0.85
1.39
1.56
2.2
2.37
2.53
2.74
2.83
3.01
2.99
2.77
2.61
2.56
2.41
Basic Weighted Avg Shares
657
765
1,435
1,500
1,556
1,592
1,606
1,599
1,587
1,760
1,616
1,573
1,518
1,511
Sales/Revenue/Turnover
1,161
1,319
2,464
2,434
2,309
2,719
2,941
2,471
2,485
2,704
2,172
1,938
1,861
1,956
Operating Margin (%)
-0.39
9.39
25.04
20.97
22.13
25.08
30.94
18.78
6.23
5.56
-7.66
2.07
-0.61
-2.2
Depreciation Expense
83
118
181
198
181
192
203
257
294
337
365
343
341
- -
Net Income, GAAP
-82
54
517
225
342
605
771
320
95
88
-420
-330
-91
-158
Effective Tax Rate (%)
- -
31.58
18.38
32.91
14.38
13.24
15.53
18.76
23.71
14.61
- -
- -
- -
- -
Profit Margin (%)
-7.07
4.06
20.96
9.25
14.82
22.25
26.2
12.94
3.83
3.25
-19.34
-17.04
-4.89
-8.06
Working Capital
-67
473
859
2,295
2,351
2,155
2,122
2,052
1,704
1,275
819
662
617
314
LT Debt
478
70
188
200
100
- -
- -
22
18
162
10
7
1
- -
Total Equity
633
3,179
3,573
4,770
5,142
5,391
5,724
5,852
6,114
6,105
5,602
5,132
5,031
4,780
Return on Invested Capital (%)
- -
1.61
12.5
4.36
5.56
9.76
12.96
5.25
1.43
1.36
- -
- -
- -
- -
Return on Capital (%)
- -
3.96
13.6
5.15
6.32
10.17
13.11
5.38
1.74
1.75
- -
- -
- -
- -
Return on Common Equity (%)
-12.3
2.81
15.26
5.39
6.91
11.49
13.87
5.52
1.59
1.44
-7.17
-6.15
-1.79
-3.17

Capital Structure

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
1,289
1,096
1,280
LT Borrowings
- -
- -
- -
LT Finance Leases
1
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
1,619
1,619
1,619
Market Capitalization
10,101
11,509
8,547

Working Capital

CNY

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
2,833
2,430
2,579
Cash, Cash Equivalents & STI
1,394
858
1,079
Accounts Receivable, Net
425
457
428
Inventories
902
984
897
Total Current Liabilities
2,216
2,023
2,265
Payables & Accruals
- -
- -
- -
ST Debt
1,289
1,096
1,280
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
4.03%
-2.85%
-1.97%
Free Cash Flow
-256.18%
-162.02%
-354.41%
Net Income, GAAP
-70.75%
-149.77%
-72.42%
Sales/Revenue/Turnover
-2.15%
-5.01%
-4.01%
Total Cash Common Dividend
25.59%
11%
-6.3%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
528
510
406
494
1,938
2025
486
439
- -
494
1,861
2026
486
536
- -
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.02
- -
-0.02
-0.22
-0.21
2025
0.01
- -
- -
-0.06
-0.06
2026
0.02
-0.06
- -
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
- -
- -
- -
0.02
2025
0.01
- -
- -
- -
0.02
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Guo Rui Xu
Full Time Employees
2,736
Sector
Health technology
Industry
Pharmaceuticals: major
Address
No. 100, Waisha Branch Road Taizhou ZH China 318000
IPO Date
Dec 26, 2006
Website
hisoar.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Zhejiang Hisoar Pharmaceutical Co., Ltd. (002099.SZ) engages in the research, development, production and sale of active pharmaceutical ingredients, pharmaceutical intermediates, generic formulations, fine chemicals, dyestuffs and dye intermediates. The company manufactures antibiotics including clindamycin series and meropenem, cardiovascular drugs such as metoprolol succinate, hypoglycemic agents like repaglinide and voglibose, anti-inflammatory agents, anti-HIV medications, anti-diabetic products and related intermediates; it also produces environmentally friendly reactive dyes such as active brilliant blue KN-R series with global market share exceeding 60%, anthraquinone dyes and pigment intermediates, alongside contract manufacturing services (CMO/CDMO) for multinational pharmaceutical companies. Over 70% of pharmaceutical products export internationally, with leading global positions in clindamycin production; operations span China with production bases in Taizhou, Yichang and Jiangsu, plus overseas entities including Genevida GmbH in Germany and Hong Kong holdings. Founded in 1966 and headquartered at No. 100 Waishazhi Road, Jiaojiang District, Taizhou, Zhejiang Province, China, the company operates as a listed entity controlled by Dankong Industry & Trade Group Co., Ltd. following its 2014 acquisition, with subsidiaries including Zhejiang Hisoar Chuannan Pharmaceutical Co., Ltd., Taizhou Qianjin Chemical Co., Ltd. and Zhejiang Qilian Environmental Protection Technology Co., Ltd. It maintains a national enterprise technology center, postdoctoral workstation and provincial research institutes focused on Haixiang Pharmaceutical and Taizhou Qianjin. Recent developments include the completion of a share repurchase program announced April 2025, acquiring 4.41 million shares or 0.28% of outstanding shares for CNY 25.59 million by September 2025; establishment of Yichang Hisoar Pharmaceutical Co., Ltd. in planning stages; and in 2020 launch of a mask production line alongside COVID-19 donations, plus formation of Zhejiang Qilian for hazardous waste management.